Pyxis Oncology (NASDAQ:PYXS – Get Free Report) and Dominari (NASDAQ:DOMH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
Institutional & Insider Ownership
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations for Pyxis Oncology and Dominari, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pyxis Oncology | 1 | 1 | 7 | 0 | 2.67 |
| Dominari | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares Pyxis Oncology and Dominari”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pyxis Oncology | $13.86 million | 12.07 | -$79.62 million | ($1.31) | -2.02 |
| Dominari | $123.10 million | 0.54 | -$22.43 million | ($4.03) | -0.72 |
Dominari has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Pyxis Oncology has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Profitability
This table compares Pyxis Oncology and Dominari’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pyxis Oncology | N/A | -135.60% | -85.00% |
| Dominari | -31.37% | -206.20% | -155.26% |
Summary
Pyxis Oncology beats Dominari on 9 of the 14 factors compared between the two stocks.
About Pyxis Oncology
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
